Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

ARASENS: Darolutamide Plus ADT and Docetaxel May Become New

Prostate Cancer Treatment (PDQ®) - PDQ Cancer Information

Prostate Cancer Treatment (PDQ®) - PDQ Cancer Information

Quick Take: Darolutamide in Advanced Prostate Cancer

Are Bacteria and AI Taking the Stealth Out of Prostate Cancer

PDF) Clinical Development of Darolutamide: A Novel Androgen

Cancers, Free Full-Text

Prostate Cancer Treatment (PDQ®) - NCI

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival

Current Oncology, Free Full-Text

View of Darolutamide (Nubeqa) Canadian Journal of Health

Prostate cancer - The Lancet

Effect of crossover from placebo to darolutamide on overall

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate